当前位置: X-MOL 学术bioRxiv. Pharmacol. Toxicol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Cancer-Associated Mutations Enhance The Sensitivity Of The Trupath GαQ/11 System
bioRxiv - Pharmacology and Toxicology Pub Date : 2022-09-02 , DOI: 10.1101/2022.09.01.506210
Dewi Safitri , Matthew Harris , Abigail Pearce , Xianglin Huang , Matthew Rosa , Kerry Barkan , Edward Wills , Maria Marti-Solano , Matthew Falk , Graham Ladds

G protein-coupled receptors (GPCRs) are the largest family of cell surface receptors and are a common drug target. They can be stabilised in different conformational states by ligands to activate multiple transducers and effectors leading to a variety of cellular responses. The potential of agonists to activate select pathways has important implications for drug discovery. Thus, there is a clear need to profile the initial GPCR signal transduction event, activation of G proteins, to enhance understanding of receptor coupling and guide drug design. The BRET-based biosensor suite, TRUPATH, was recently developed to enable quantification of the activation profiles of all non-visual G proteins (excluding Golf and G14) and has since been utilised in numerous studies. However, it fails to detect Gq/11 activation for a number of GPCRs previously reported to display promiscuous secondary coupling to Gq/11. Here we report modifications to the Gαq and Gα11 biosensors in the switch I region that prevent intrinsic GTPase activity (R183C/Q). Except for the PAC1R, substitution with cancer-associated mutations, Cys or Gln, significantly increased sensitivity to allow detection of robust, reliable, and representative Gq/11 responses to Class B1 GPCRs. We also demonstrate the utility of these modified biosensors for promiscuously coupled class A GPCR that have primary Gs-coupling. Thus, we propose that modification to Gαq/11 may also be necessary in other biosensor systems to enable detection of Gq/11 activation.

中文翻译:

癌症相关突变增强了 Trupath GαQ/11 系统的敏感性

G 蛋白偶联受体 (GPCRs) 是最大的细胞表面受体家族,是常见的药物靶点。它们可以通过配体稳定在不同的构象状态,以激活多个传感器和效应器,从而导致各种细胞反应。激动剂激活选择途径的潜力对药物发现具有重要意义。因此,显然需要分析初始 GPCR 信号转导事件、G 蛋白的激活,以增强对受体偶联的理解并指导药物设计。最近开发了基于 BRET 的生物传感器套件 TRUPATH,以实现对所有非视觉 G 蛋白(不包括 G olf和 G 14) 并已被用于许多研究。然而,它未能检测到先前报道的许多 GPCR 的 G q/11激活,这些 GPCR 显示出与 G q/11的混杂二次耦合。在这里,我们报告了对开关 I 区域中 Gα q和 Gα 11生物传感器的修改,这些修改阻止了内在的 GTPase 活性 (R183C/Q)。除 PAC1R 外,癌症相关突变 Cys 或 Gln 的替代显着提高了灵敏度,以允许检测对 B1 类 GPCR 的稳健、可靠和有代表性的 G q/11反应。我们还展示了这些修改后的生物传感器对于具有初级 G s的混杂耦合的 A 类 GPCR 的效用-耦合。因此,我们建议在其他生物传感器系统中也可能需要对 Gα q/11进行修改,以检测 G q/11激活。
更新日期:2022-09-04
down
wechat
bug